Neurontin
Product Images NDC 16590-870

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Neurontin (NDC 16590-870). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Stat Rx Usa Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Neurontin 400mg Label 870)

Neurontin 400 mg capsule bottle label distributed by STAT RX USA LLC. The label shows 84 capsules per container and states the active ingredient is gabapentin 400 mg per capsule. Manufactured by Pfizer Inc. in New York, with directions to store between 59-86°F and discard after 03/13. Includes a barcode and warnings to keep medication out of reach of children and for prescription use only.*

FDA Label Image

Chemical Structure (Neurontin 01)

Chemical structure of gabapentin, the active ingredient in Neurontin. The diagram shows a cyclohexane ring attached to an aminomethyl group and an acetic acid moiety.*

FDA Label Image

Figure (Neurontin 02)

A line graph comparing mean pain scores over 8 weeks between placebo and Gabapentin 3600 mg/day groups. The x-axis shows weeks, including baseline, with distinct 4-week dose titration and 4-week fixed dose periods. Gabapentin group's pain score decreases notably compared to placebo throughout the study.*

FDA Label Image

Figure (Neurontin 03)

A line graph depicting mean pain scores over a 7-week period comparing placebo, gabapentin 1800 mg/day, and gabapentin 2400 mg/day. The timeline includes a 3-week dose titration period followed by a 4-week fixed dose period. Gabapentin treatments show lower pain scores compared to placebo, with statistical significance noted (p < 0.01).*

FDA Label Image

Figure (Neurontin 04)

A bar chart showing the percentage of responders at endpoint in two studies comparing placebo (PBO) with two dosages of GBP (Gabapentin) 3600 mg in Study 1, and 1800 mg and 2400 mg in Study 2. The chart indicates statistically significant higher responder percentages for GBP groups compared to placebo, with values around 29% and 32-34% for GBP groups versus 12-14% for placebo groups.*

FDA Label Image

Figure (Neurontin 05)

A scatter plot depicting the relationship between daily dose (mg) on the x-axis and difference (%) on the y-axis. Data points represent three studies labeled as study a, study b, and study c, with varying values across doses of approximately 600, 900, 1200, and 1800 mg daily.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.